Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/32336

Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability


no-thumbnailVer/Abrir:

 Evaluation of agomelatine for the.pdf



726,54 kB
Adobe PDF
Compartir:

Este recurso está restringido

Título :
Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability
Autor :
Ballester, Purificación
Martínez, María José
Inda, María del Mar
Javaloyes, María Auxiliadora  
Richdale, Amanda  
Muriel, Javier  
Belda, César
Toral, Natalia
Morales, Domingo  
Fernández, Eduardo
Peiró, Ana  
Editor :
Sage Journals
Departamento:
Departamentos de la UMH::Farmacología, Pediatría y Química Orgánica
Fecha de publicación:
2019-11
URI :
https://hdl.handle.net/11000/32336
Resumen :
Purpose: Intellectual disability (ID) and autism spectrum disorder (ASD) are common, co-occurring developmental disorders and are frequently associated with sleep problems. This study aimed to assess the effectiveness and tolerability of agomelatine as a pharmacotherapy for sleep problems in ASD adults with ID. Method: A randomised, crossover, triple-blind, placebo-controlled clinical trial, with two three-month periods of treatment starting with either agomelatine or placebo and a washout period of two weeks. Ambulatory circadian monitoring (24 hours/7 days) evaluated total sleep time (TST) as the primary outcome variable. Results: Participants (N=23; 35±12 years old; 83% male) had a median of three (interquartile range (IQR) 1-4) co-morbidities and were taking a median of five (IQR 2-7) prescribed drugs. Before agomelatine or placebo treatment, all subjects presented with insomnia symptoms, including sleep latency (100% abnormal, 55±23 minutes) or TST (55% abnormal, 449±177 minutes), and 66% had circadian rhythm sleep-wake abnormalities with rhythm phase advancements according to the M5 sleep phase marker values. During the three-month agomelatine treatment, night TST significantly increased by a mean of 83 minutes (16% abnormal, 532±121 minutes), together with a phase correction (M5 1:45±2:28 hours vs. 3:15±2:20 hours), improving sleep stability in wrist temperature rhythm (0.43±0.29 vs. 0.52±0.18 AU). Adverse events were mild and transient. Conclusions: Agomelatine was effective and well tolerated for treating insomnia and circadian rhythm sleep problems present in adults with ASD and ID.
Palabras clave/Materias:
Autism spectrum disorder
agomelatine
ambulatory circadian monitoring
circadian rhythm
sleep problems
Área de conocimiento :
CDU: Ciencias aplicadas: Medicina: Farmacología. Terapéutica. Toxicología. Radiología
Tipo de documento :
info:eu-repo/semantics/article
Derechos de acceso:
info:eu-repo/semantics/closedAccess
DOI :
https://doi.org/10.1177/0269881119864968
Aparece en las colecciones:
Artículos Farmacología, Pediatría y Química Orgánica



Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.